These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22408262)

  • 1. Efficacy of vorinostat in a murine model of polycythemia vera.
    Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
    Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
    Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time bioluminescence imaging of polycythemia vera development in mice.
    Ma Y; Zhao S; Zhu J; Bettano KA; Qu X; Marshall CG; Young JR; Kohl NE; Scott ML; Zhang W; Wang Y
    Biochim Biophys Acta; 2009 Nov; 1792(11):1073-9. PubMed ID: 19715759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
    Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
    Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
    Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
    Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
    J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
    Chen Y; Shan Y; Lu M; DeSouza N; Guo Z; Hoffman R; Liang A; Li S
    Cancer Res; 2017 Jan; 77(1):164-174. PubMed ID: 27784744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.